• Alfuzosin HCl: α1-Adrenoceptor Mechanisms

  2026-09-04

  Alfuzosin HCl is a functionally uroselective α1 adrenoceptor antagonist that reduces prostatic and bladder-neck smooth-muscle tone in benign prostatic hyperplasia research. Its pharmacology, formulation options, analytical ranges, and handling requirements support controlled in vitro and translational workflows.

• Metoprolol Workflows for Translational Research

  2026-09-04

  Metoprolol provides a focused way to interrogate beta1-adrenergic signaling in cardiovascular models while supporting exploratory inflammation, tumor, and angiogenesis workflows. This guide translates disease-aware pharmacokinetic principles into practical assay design, controls, and troubleshooting decisions.

• AO/PI Staining Solution for Better Assay Decisions

  2026-09-03

  AO/PI Staining Solution converts membrane integrity into a practical live/dead readout for fluorescence-based cell counting. This guide shows how to use dual fluorescent DNA dyes as a quality-control layer in diabetic nephropathy workflows without confusing viability measurements with mechanistic proof.

• EGCG Nanoparticles Enhance FLASH-RT Antitumor Effects

  2026-09-03

  A 2026 International Journal of Nanomedicine study reports that functionalized, self-assembled EGCG nanoparticles, termed BENPs, can intensify FLASH-RT-induced reactive oxygen species, DNA damage, tumor-cell death, and antitumor immunity. The work provides a preclinical strategy for addressing the limited tumor-control advantage of FLASH-RT while highlighting γ-H2AX-centered measurements for DNA damage and repair research.

• Cy7 NHS Ester: Practical Labeling Guide

  2026-09-02

  Cy7 NHS ester is a water-soluble protein labeling dye for preparing near-infrared conjugates of proteins, peptides, and other amino-containing biomolecules. It is suited to near-infrared fluorescent imaging and live-cell or tissue workflows, but the reagent solution should be prepared freshly and the product should not be treated as a validated substitute for model-specific stability, toxicity, or biodistribution studies.

• Biomimetic Chromatography for Pulmonary Permeability

  2026-09-02

  The reference study provides a direct comparison of immobilised artificial membrane liquid chromatography and liposome electrokinetic capillary chromatography for modelling drug–membrane partitioning and pulmonary permeability. Its findings indicate that LEKC can better reflect membrane-related determinants of lung permeability, whereas IAM LC offers broader compound coverage and simpler high-throughput implementation.

• Tobramycin: Practical MIC & Resistance Workflows

  2026-09-01

  Tobramycin provides a water-compatible way to build reproducible broth microdilution, comparative susceptibility, and antibiotic resistance research workflows. This guide translates a classic aminoglycoside study into practical assay design, preparation, controls, and troubleshooting for modern microbiology research.

• Bifendate–Cyclosporine Interaction by CYP3A4 Genotype

  2026-09-01

  The 2009 study by Zeng and colleagues showed that bifendate lowers cyclosporine exposure and increases its oral clearance, with the largest effect in healthy subjects carrying two CYP3A4*18B alleles. Its randomized crossover design provides a useful human pharmacogenetic model for evaluating DDB as a CYP3A4-related drug–drug interaction risk, particularly when cyclosporine has a narrow therapeutic index.

• PYR-41 for E1 and Antiviral Ubiquitin Research

  2026-08-31

  PYR-41 enables pathway-level interrogation of ubiquitin activation, protein stability, NF-κB signaling, and antiviral defense. This guide translates E1 inhibition into practical cell-based workflows while clearly separating validated product performance from hypothesis-generating applications in IBDV and sepsis inflammation models.

• Caffeine Workflows for Cancer and Metabolic Research

  2026-08-30

  Caffeine enables controlled studies of adenosine signaling, cancer cell line inhibition, and energy metabolism modulation in practical in vitro and in vivo workflows. This guide pairs product-specific handling with assay design lessons from recent ALDH2 activator research, while clearly separating validated evidence from exploratory applications.

• Pharmacological Chaperones Rescue GABAA Variants

  2026-08-29

  The reference study shows that epilepsy-associated GABAA receptor α1 variants can cause loss of function by disrupting folding, assembly, trafficking, and degradation rather than simply altering channel activity. Hispidulin and TP003 improved functional surface expression without activating the unfolded protein response, supporting a receptor-specific pharmacological chaperone strategy for genetic epilepsy.

• Prochlorperazine in Melanoma: COLO829 and C32 Evidence

  2026-08-29

  The 2019 reference study evaluated prochlorperazine and perphenazine across melanotic COLO829 and amelanotic C32 melanoma cells, combining viability, motility, and melanocytic marker analyses. Its main contribution is evidence that prochlorperazine can suppress melanoma-cell viability and wound closure in vitro while altering MITF and tyrosinase, creating a mechanistic basis for further melanoma research rather than a clinical treatment claim.

• IGF2BP1–THBS1 Axis in Pulmonary Fibrosis

  2026-08-28

  The reference study identifies an m6A-dependent IGF2BP1–THBS1–TLR4 pathway that links macrophage glycolytic reprogramming with fibrotic polarization during pulmonary fibrosis. Its knockdown, overexpression, and rescue experiments provide a mechanistic framework for interpreting how RNA stability and macrophage metabolism may influence lung pathology.

• H-89 and the Wnt–PKA–O-GlcNAc Axis

  2026-08-28

  A translational framework for using H-89 to test how cAMP-dependent PKA activity links Wnt signaling, O-GlcNAcylation, glycolysis, and osteoblast function.

• Midecamycin In Vitro Activity: 1983 Study Analysis

  2026-08-27

  Harold C. Neu’s 1983 study established the antibacterial spectrum of Midecamycin, an acetoxy-substituted macrolide antibiotic, across clinically recovered Gram-positive and Gram-negative isolates. The paper showed useful activity against many streptococci, staphylococci, Haemophilus influenzae, and Listeria, but substantially weaker activity than erythromycin and no meaningful activity against erythromycin-resistant or many Gram-negative organisms.

457 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page